Jideytro

(Zidesamtinib (NVL-520))

PreclinicalSmall molecule

NNuvalent Inc.

Jideytro is one of 14 small molecule programs targeting Other Solid Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Other Solid TumorsRecruiting

Locally Advanced Solid TumorRecruiting

Other Solid TumorsPreclinical

Recruiting

Locally Advanced Solid TumorPreclinical

Recruiting

Competition

Competitive Landscape

9 competitors in Other Solid Tumors

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 2

2 2

Erbitux

IImclone

Phase 2

1 3

JAB 21822

AAllist Pharmaceuticals, Inc.

Phase 2

1 4

Tuoyi

CCoherus Oncology, Inc.

Phase 1

1 5

MCLA-129

BBetta Pharmaceuticals Co., Ltd.

Phase 2

1 6

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 1

1 7

Neladalkib (NVL-655)

NNuvalent Inc.

Phase 2

1 8

Jideytro

NNuvalent Inc.

Preclinical

1 9

HBM4003

HHarbour BioMed (Guangzhou) Co. Ltd.

Phase 1

2 10

HQP1351

Ascentage Pharma Group Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Locally Advanced Solid Tumor

NCT05118789

Clinical

Trials by Indication[1]

Locally Advanced Solid Tumor1 trial

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)

Recruiting·NNuvalent Inc.·Preclinical·NCT05118789·359 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 21, 2026

JIDEYTRO

NDA NDA220185

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zidesamtinib (NVL-520). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zidesamtinib (NVL-520) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zidesamtinib (NVL-520). EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA220185). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Jideytro. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Nuvalent Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNuvalent Inc.

Patent Landscape[5]

Patent Cliff

May 4, 2041

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12054498May 4, 2041

11542278May 4, 2041

12630560Sep 29, 2042

12043626Sep 29, 2042

Jideytro

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Locally Advanced Solid Tumor1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News